Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe ...
Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...
Oral presentation on novel allosteric ELXR epigenetic silencer showcases Scribe’s development in achieving highly precise, potent, and durable target repression XE gene editor oral presentation ...
Scribe Therapeutics, Inc. (Scribe), a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results